Trial site
Florida Cancer Specialists - Sarasota
Sarasota, Florida 34232, United StatesNot linked to an institution yet
- 18running trials
- 1closed trial
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 19 trials
- Phase 24 trials
- Phase 34 trials
- Status
- Active, not recruiting12 trials
- Recruiting6 trials
- Completed1 trial
- Lead sponsor
- National Cancer Institute (NCI)6 trials
- NRG Oncology3 trials
- Eli Lilly and Company2 trials
- Genentech, Inc.2 trials
- Abdera Therapeutics Inc.1 trial
- and 5 more
Running trials
Recruiting
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616· Phase 1· SystImmune Inc.· Source
Contact: Judy Wang (principal investigator)
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923· Phase 1· Eli Lilly and Company· Source
Recruiting
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06532279· Phase 2· NRG Oncology· Source
Contact: Kunal Saigal (principal investigator)
Active, not recruiting
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418· Phase 1· Abdera Therapeutics Inc.· Source
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664· Phase 1· Compass Therapeutics· Source
Contact: Judy Wang, MD (principal investigator)
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Pavankumar Tandra (principal investigator)
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304· Phase 1· Erasca, Inc.· Source
Active, not recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004· Phase 1· Genentech, Inc.· Source
Active, not recruiting
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045· Phase 1· Jazz Pharmaceuticals· Source
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Source
Contact: Toni P. Kilts (principal investigator)
Active, not recruiting
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874· Phase 1· Genentech, Inc.· Source
Active, not recruiting
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
NCT03348631· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826· Phase 2· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error